The safety of JAK-1 inhibitors

As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Benjamin, Yates, Mark, Adas, Maryam, Bechman, Katie, Galloway, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098103/
https://www.ncbi.nlm.nih.gov/pubmed/33950230
http://dx.doi.org/10.1093/rheumatology/keaa895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098103/
https://www.ncbi.nlm.nih.gov/pubmed/33950230
http://dx.doi.org/10.1093/rheumatology/keaa895

Ejemplares similares